| P/E (FY) | — | Sales (TTM) | $8.8M |
| Earnings (TTM) | -$111.1M | ROE | −41.44% |
| Net Margin | — | ROIC | −138.72% |
| Debt / Equity | 0.01 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Perspective Therapeutics is a radiopharmaceutical development company that develops and commercializes precision targeted alpha therapies to treat cancer in the United States. Its candidates include VMT-a-NET, in Phase 1/2a trials for neuroendocrine tumors; VMT01, in Phase 1/2a trials for metastatic melanoma; and PSV359, targeting fibroblast activation protein alpha. The company also develops the beta-emitting radioligand therapy Pluvicto for prostate cancer.
| Market Cap | $327.3M | Trading Days | 840 |
| 52W High | 6.16 |
| 52W Low | 1.96 |
| % Off High | −53.41% |
| YTD | 4.36% | 1Y | −30.34% |
| 3Y | −51.36% | Since incept. (ann.) | −14.42% |
| Ann. Volatility (1Y) | 110.89% | Ann. Volatility (3Y) | 112.69% |
| Sharpe (1Y) | 0.15 | Sharpe (3Y) | 0.34 |
| Max Drawdown (1Y) | −58.84% | Max Drawdown (3Y) | −90.71% |
| Beta (3Y, vs SPY) | 0.95 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | $327.1M | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $328.9M | — |
| ORGO | Organogenesis Holdings Inc. | $325.5M | 16.9 |
| AKBA | Akebia Therapeutics, Inc. | $340.7M | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $342.9M | — |
| ABEO | ABEONA THERAPEUTICS INC. | $343.1M | 6.0 |
| VNDA | Vanda Pharmaceuticals Inc. | $310.3M | — |
| UPB | Upstream Bio, Inc. | $348.3M | — |
| LYEL | Lyell Immunopharma, Inc. | $303.1M | — |
| FHTX | Foghorn Therapeutics Inc. | $301.2M | — |
| DMAC | DiaMedica Therapeutics Inc. |
| $357.8M |
| — |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
